Page 5 of 26, showing 50 records out of 1263 total, starting on record 201, ending on 250
| Publication |
Category |
Year |
|
168. Labrie, C., Simard, J., Zhao, H.F., Bélanger, A., Pelletier, G., Labrie, F. (1990) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 395-398. |
All publications |
1990 |
|
169. Labrie, C., Simard, J., Zhao, H.F., Pelletier, G., Labrie, F. (1990) Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol. Cell. Endocrinol., 68: 169-179. |
All publications |
1990 |
|
158. Labrie, C., Trudel, C., Li, S., Martel, C., Couët, J., Labrie, F. (1991) Combination of an antiandrogen and a 5a-reductase inhibitor: a further step towards total androgen blockade? Endocrinology, 129: 566-568. |
All publications |
1991 |
|
170. Labrie, F. (1990) Goserelin study criticized. Oncology Times, 10: 18-19. |
All publications |
1990 |
|
171. Labrie, F. (1990) Peripheral tissues are important sites of sex steroid formation in the human: a new field of endocrinology which extends from gene structure to therapy that prolongs life in prostate cancer. Physiol Canada, 13th Sarrazin Lecture, 21: 66-99. |
All publications |
1990 |
|
159. Labrie, F. (1991) Endocrine therapy for prostate cancer, in: Strauss, J.F., ed. Endocrinology and Metabolism Clinics of North America, Philadelphia, W.B. Saunders, pp 845-872. |
All publications |
1991 |
|
160. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. |
All publications |
1991 |
|
3951. Labrie, F. (1992) Faits et logique. Médecine/Sciences, 8: 708-9. |
All publications |
1992 |
|
149. Labrie, F. (1992) Stratégie efficace et peu coûteuse pour la détection du cancer de la prostate à un stade précoce alors que la guérison est possible. Médecine/Sciences, 8: 703-706. |
All publications |
1992 |
|
3921. Labrie, F. (1993) Advances in Diagnosisi and Treatment of early stage prostate cancer. Symposium Proceedings, Quebec City, May 9-30. Clinical and Investigative Medicine, 16: 407-538. |
All publications |
1993 |
|
134. Labrie, F. (1993) GNRH agonists in prostate cancer, in GnRH analogues - The State of the Art 1993, New York, Parthenon Publishing, pp 103-121. |
All publications |
1993 |
|
135. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. |
All publications |
1993 |
|
3915. Labrie, F. (1993) Let me count the ways. Scientific evaluation. Measure for Measure in Science [Letter to the Editor re: Taubes 260: 884-6, 1993]. Science, 261: 145. |
All publications |
1993 |
|
136. Labrie, F. (1993) Mechanism of action and pure antiandrogenic properties of Flutamide. Cancer, 72: 3816-3827. |
All publications |
1993 |
|
137. Labrie, F. (1993) Non-steroidal antiandrogens, in: Droz, J.P., Cvitkovic, E., Armand, J.P. et Khoury, S., eds: Handook of Chemotherapy in Clinical Oncology, London, Scientific Communication International Ltd., pp 389-391. |
All publications |
1993 |
|
138. Labrie, F. (1993) Present status of endocrine therapy of prostate cancer. Eur. Urol. Today, 3: 10-11. |
All publications |
1993 |
|
124. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. |
All publications |
1994 |
|
125. Labrie, F. (1994) Les antiandrogènes dans le cancer de la prostate. La Lettre du Pharmacologue, 8: 190-195. |
All publications |
1994 |
|
126. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to 342: 901-5, 1993]. Lancet, 343: 491. |
All publications |
1994 |
|
127. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to Cheney re 343: 491-2, 1994]. Lancet, 343: 976-977. |
All publications |
1994 |
|
3878. Labrie, F. (1994). The reply to: Acute cholestatic hepatitis secondary to Flutamine therapy. The American Journal of medecine, 96: 392-393. |
All publications |
1994 |
|
110. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab., 80: 1066-1071. |
All publications |
1995 |
|
81. Labrie, F. (1997) Flutamide plus castration in patients with previously untreated prostate cancer [Letter to the Editor re: Noldus et al. 47: 713-8, 1996]. Urology, 50: 479. |
All publications |
1997 |
|
3751. Labrie, F. (1997) Reply by the author to: Conflict of interest or widely held misconception. Urology, 50: 1028. |
All publications |
1997 |
|
3749. Labrie, F. (1997) Why the brain drain matters. The Globe and Mail, A25. |
All publications |
1997 |
|
810. Labrie, F. (1999) Internal symposium: Editorial. Xth International Congress on Hormonal Steroids (Quebec City, Canada 17-21 June 1998). J. Steroid Biochem. Mol. Biol., 69: 1. |
All publications |
1999 |
|
3667. Labrie, F. (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer trialists' Collaborative Group. Lancet, 355: 1491-8. |
All publications |
2000 |
|
48. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. |
All publications |
2000 |
|
4717. Labrie, F. (2001) Dehydroepiandrosterone (DHEA) as potential hormone replacement therapy. Références en Gynecologie Obstétrique, 8: 317-322. |
All publications |
2001 |
|
38. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. |
All publications |
2001 |
|
3637. Labrie, F. (2001) The Role of Androgen Therapy in Postmenopausal Women - Physiology of Androgens in Women. Supplement to Menopause Management, 11: 3-5. |
All publications |
2001 |
|
3638. Labrie, F. (2001) Unique role of hormone therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate cancer: biology, diagnosis and management, pp 301-314. |
All publications |
2001 |
|
33. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. |
All publications |
2002 |
|
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
All publications |
2002 |
|
672. Labrie, F. (2003) Extragonadal synthesis of sex steroïds: Intracrinology. Ann. Endocrinol, 64: 95-107. |
All publications |
2003 |
|
30. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. |
All publications |
2003 |
|
3603. Labrie, F. (2003) Médecin spécialiste en endocrinologie, in : Media, Q., ed. 100 carrières de la santé et des services sociaux, Montréal, Canada, Jobboom les éditions, pp 122. |
All publications |
2003 |
|
3577. Labrie, F. (2004) Adrenal Androgens and Intracrinology, in: Bruce R. Carr, M.D., eds. Seminars in Reproductive Medicine, New York - Stuttgart, pp 299-309. |
All publications |
2004 |
|
21. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. |
All publications |
2004 |
|
22. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. |
All publications |
2004 |
|
23. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. |
All publications |
2004 |
|
24. Labrie, F. (2004) Status of androgen blockade in prostate cancer in 2003, in: Koutsilieris, M. et Labrie, F., eds: Prostate cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 157-170. |
All publications |
2004 |
|
573. Labrie, F. (2006) Dehydroepiandrosterone, androgens and the mammary gland. Gynecological Endocrinol: the official journal of the International Soc. of Gynecological Endocrinol, 22: 118-30. |
All publications |
2006 |
|
380. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. |
All publications |
2006 |
|
16. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
All publications |
2006 |
|
355. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. |
All publications |
2007 |
|
7. Labrie, F. (2007) Multiple intracrine hormonal targets in the prostate: oportunities and challenges. BJU Int, 100: 48-51. |
All publications |
2007 |
|
374. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. |
All publications |
2008 |
|
4694. Labrie, F. (2008) Comment to: Prostate specific antigen (PSA)-based screening. Int J Urol, 15: 757-762. |
All publications |
2008 |
|
4710. Labrie, F. (2010) DHEA after Menopause – Sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management. 19: 14-24 |
All publications |
2010 |